NCT04544969 Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
| NCT ID | NCT04544969 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Circulating Tumor Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2020-04-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2020-04-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting patient's treatment efficacy with CTCs dynamic change.
Eligibility Criteria
Inclusion Criteria: * NPC patients with distant metastasis after 3 months of primary radiotherapy, and not suitable for local treatment * At least having one measurable metastatic lesion * All genders，range from 18～70 years old * ECOG score 0 \~ 1 * Expected survival time ≥ 3 months * White blood cell(WBC) count ≥ 3×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, hemoglobin(HGB) ≥ 90g/L, platelet(PLT) count ≥ 100×109/L * Alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \< 2.5×upper limit of normal(ULN), bilirubin(BUN) or creatinine(CRE) \< 1.5×ULN, alanine aminotransferase (CCR) ≥ 60ml/min * Inform consent form Exclusion Criteria: * Have or are suffering from other malignant tumors; * Participating in other clinical trials; * Drug or alcohol addition; * Do not have full capacity for civil acts; * Mental disorder; * Pregnancy or lactation; * Severe complication, eg, uncontrolled hypertension.
Contact & Investigator
Chong Zhao, M.D
PRINCIPAL INVESTIGATOR
Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT04544969 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Circulating Tumor Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04544969 currently recruiting?
Yes, NCT04544969 is actively recruiting participants. Contact the research team at miaojingjing90@163.com for enrollment information.
Where is the NCT04544969 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT04544969 clinical trial?
NCT04544969 is sponsored by Sun Yat-sen University. The principal investigator is Chong Zhao, M.D at Sun Yat-sen University. The trial plans to enroll 50 participants.